SCHEMBL23940250

SCHEMBL23940250

CCNC(=O)c1cn(C)c2ccccc12

nearest known ligand 0.74

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
BRD4 O60885 1/20 0.71
HDAC1 Q13547 2/20 0.61
HDAC2 Q92769 1/20 0.61
LMNA P02545 4/20 0.60
NR4A2 P43354 1/20 0.60
ALDH1A1 P00352 3/20 0.59
KMT2A Q03164 2/20 0.59
MITF O75030 1/20 0.59
MAPT P10636 1/20 0.59
NPSR1 Q6W5P4 1/20 0.59
POLB P06746 1/20 0.56
HTT P42858 1/20 0.55
SMN1; SMN2 Q16637 1/20 0.54
BCHE P06276 1/20 0.53
ACHE P22303 1/20 0.53
HDAC3 O15379 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28968558 0.85 HDAC1 (0.58) BRD4HDAC1HDAC2LMNANR4A2
SCHEMBL6586386 0.84 NR4A2 (0.64) HDAC1HDAC2LMNANR4A2ALDH1A1
SCHEMBL4104715 0.84 ALDH1A1 (0.64) BRD4HDAC1HDAC2LMNANR4A2
SCHEMBL23940223 0.84 HDAC1 (0.57) BRD4HDAC1HDAC2LMNANR4A2
SCHEMBL23940245 0.82 ALDH1A1 (0.83) HDAC1HDAC2LMNANR4A2ALDH1A1
SCHEMBL23940201 0.82 HDAC1 (0.56) BRD4HDAC1HDAC2LMNANR4A2
SCHEMBL8999213 0.82 EGFR (0.60) HDAC1HDAC2LMNANR4A2ALDH1A1
SCHEMBL1093252 0.82 BRD4 (0.69) BRD4HDAC1HDAC2LMNANR4A2
SCHEMBL9157388 0.81 HDAC1 (0.61) HDAC1HDAC2LMNANR4A2ALDH1A1
SCHEMBL23940148 0.81 HDAC1 (0.65) BRD4HDAC1HDAC2LMNANR4A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210323966-A1 IMIDAZOPYRIDAZINE COMPOUNDS BRISTOL-MYERS SQUIBB COMPANY (US) 2021-10-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210323966-A1 IMIDAZOPYRIDAZINE COMPOUNDS TYK2, JAK3, JAK1 BRD4 753/4885HDAC1 714/4885HDAC2 327/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.